KRAS and non-small cell lung carcinoma: However, the development of new systemic anticancer therapies (SACT) such as anti-angiogenic agents, immune checkpoint inhibitors (ICIs) and therapies that target specific alterations (e.g., endothelial growth factor receptor, anaplastic lymphoma kinase, Kristen rat sarcoma (KRAS)) [7,8] have led to a shift in the treatment landscape for NSCLC.